UroAlert - GU Oncology Daily

June 10, 2026

Videos

Peer-to-Peer Clinical Conversations

BCG-Unresponsive Bladder Cancer Care in Community Practice - Gautam Jayram

Gautam Jayram

Gautam Jayram discusses real-world challenges in delivering BCG-unresponsive bladder cancer therapies in community practice.

More Than a Diagnosis: Global Survey Exposes the Emotional and Physical Toll of Bladder Cancer Treatment - Gina Carithers

Gina Carithers

Gina Carithers reflects on the Bladder Burden Survey and patient advocacy, discussing her role moderating the panel held before AUA 2026.

Beyond the Abstracts

A Systematic Review of Gene-Mediated Therapy in BCG-Unresponsive NMIBC: Emerging Evidence and Future Perspectives - Beyond the Abstract

End-of-Life and Palliative Care in Patients with Metastatic Renal Cancer - Beyond the Abstract

Conference Coverage

ASCO 2026: A Phase 3 Randomized, Open-Label Study of Pasritamig (JNJ-78278343), a T-Cell Engager Targeting Human Kallikrein-2, with Docetaxel Versus Docetaxel for Metastatic Castration-Resistant Prostate Cancer

ASCO 2026: Effect of On-Treatment Dose Adjustments on the Efficacy of Enfortumab Vedotin and Pembrolizumab (EV + Pembro) in Advanced Urothelial Carcinoma (aUC): A UNITE Analysis

ASCO 2026: Outcomes with 1L Platinum-Based Chemotherapy and Avelumab 1L Maintenance in la/mUC by NECTIN4 and HER2 RNA Expression: Exploratory Analyses from JAVELIN Bladder 100

ASCO 2026: Outcomes with Enfortumab Vedotin Rechallenge After Disease Progression in Metastatic Urothelial Carcinoma.

AUA 2026: The ENLIGHTED Phase 3 Trial: Advancing Treatment of Low-Grade Upper Tract Urothelial Carcinoma (LG UTUC) with Padeliporfin Vascular-Targeted Photodynamic Therapy (VTP)

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Targeting HER2 in Urothelial Carcinoma: Why Histologic Subtypes and Divergent Histologies Matter.

Mixture cure model analysis of event-free survival in the NIAGARA Trial: Quantifying the cure fraction benefit of perioperative durvalumab in muscle-invasive bladder cancer.

Renal Cancer

Lactate-Activated GPR132 Signaling Drives a Tumor Microenvironmental Autocrine Metabolic Loop in Kidney Cancer.

ILT2 identifies an unexploited pool of intratumoral CD8+ bystander T cells with TCR-independent cytotoxicity in renal cell carcinoma.

Prostate Cancer

Enhanced Telehealth in Prostate Cancer.

Comparison of automated bone scan indexes in patients with prostate cancer: aBSI and BONENAVI.

Salvage prostatectomy for locally recurrent prostate cancer after radiation: a narrative review of indications, outcomes, and surgical advancements.

Real-World Clinical Evaluation of S2,3PSA Test in a Prostate Biopsy Cohort With PSA Level of 4-10 ng/mL.

177Lutetium-PSMA-I&T therapy for metastatic castration-resistant prostate cancer (mCRPC): the first multicenter real-world study of 177Lu-PSMA-I&T in Brazil.

Implementing intervention mapping to tailor the evidence-based PREDIMED intervention for medically underserved prostate cancer patients.

Neoadjuvant Fc-Enhanced Anti-CTLA-4 Targets Tregs to Augment Androgen Deprivation in High-Risk Prostate Cancer: A Randomized Phase I Trial - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC